ClinicalTrials.gg
CompletedNCT05932888Updated Sep 21, 2023

Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects

A Phase 1 interventional study of QLM3003 and QLM3003 Placebo in Atopic Dermatitis, sponsored by Qilu Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
161st of 190
40 · median 164
Started
2023
with 38 others
Phase 1
38 of 206
14 open now
Registered
75th of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 161st largest by enrollment of the 190 interventional ones that give a count, is one of 39 that started in 2023, is one of 38 in phase 1, and was the 75th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) doses of QLM3003 compared to placebo. Also, pharmacokinetics (PK) of qlm3003 will be evaluated.

Read the detailed description

The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) doses of QLM3003 compared to placebo. Also, pharmacokinetics (PK) of qlm3003 will be evaluated.Eligible subjects will be assigned to a sequential treatment cohort and randomized to each treatment group (active/placebo ). Subject enrollment will continue into the next cohort after review of the dose safety from the previous dose cohort.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult subjects between 18-55 years of age (inclusive), male or female
  2. The (BMI equal to body mass/square of body height) of the subjects ranges from 19 to 26 kg/m2 (inclusive), and males of weight not less than or equal to 50 kg, females of weight not less than or equal to 45 kg.
  3. Subjects have no sperm donation, egg donation plan, no pregnancy plan and voluntarily take effective measures from 14 days before signing the form to 30 days after the last dose of product;
  4. The subjects understand and comply with the study requirements, voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Patients who are allergic to the product or its preparation ingredients, or have previous allergic diseases, history of drug allergy, history of skin allergy, or known to be hypersensitive;
  2. Patients with skin diseases that are in the study or affect the assessment of the administration site at screening, including but not limited to psoriasis, eczema, acne, atopic dermatitis, dysplastic mole, or other skin lesions, and a history of skin cancer;
  3. Skin conditions affecting the assessment of the study drug such as ulceration, injury, sunburn, redness and swelling, rash, or abnormal fever, tattoos, birthmarks, skin scars, skin perforations, skin infections on the skin of the target application area at screening and before administration, or disagreeing to removing the hair on the skin of this site;
  4. Pregnant or lactating women, and those who cannot use one or more non-drug measures during the trial;
  5. Patients who have difficulty in collecting blood or cannot tolerate venipuncture, and have a history of fainting needle halo;
  6. Those who have special requirements for diet and cannot abide by the unified diet;
  7. Excessive consumption of tea, coffee or caffeinated beverages, or consumption of grapefruit, or xanthine-rich foods or beverages within 14 days before screening, or inability to stop consumption of xanthine-rich foods or beverages, or grapefruit or pomelo and products containing grapefruit or pomelo ingredients within 48 hours before dosing and during the trial;
  8. Patients who smoked more than 5 cigarettes or the same amount of tobacco daily for 3 months before screening and could not stop using any tobacco products during the trial;
  9. Regular drinkers within 6 months before screening, i.e., those who drank more than 14 units of alcohol per week or could not stop using any alcohol-containing products during the trial; or those who took any alcohol-containing products within 48 hours before the first dose, or those who tested positive for alcohol breath before randomization;
  10. Drug abusers or those who have used soft drugs within 3 months before screening or hard drugs within 1 year before screening or those who have positive drug abuse screening before randomization;
  11. Blood donation or massive blood loss, receiving blood transfusion or using blood products within 3 months before screening;
  12. Any surgical procedure within 30 days prior to Screening or planned during the study and within 30 days after the end of the study;
  13. Patients who have received any within 30 days before screening or need to receive live vaccines during the study;
  14. Use of any drug that inhibits or induces hepatic metabolism of the drug within 30 days before screening;
  15. Patients who have taken any drug or health product within 14 days before screening;
  16. Patients who have participated in and used any drug or medical device clinical trials within 3 months before screening, or within 5 half-lives of other investigational drugs before screening;
  17. Patients with previous serious or clinically significant diseases or abnormalities at screening, including but not limited to cardiovascular system, nervous system, respiratory system, blood and lymphatic system, digestive system, immune system, liver, kidney, metabolism and bone system diseases or psychiatric diseases or history of malignant tumors;
  18. Abnormal vital signs or clinically significant abnormalities in physical examination, and laboratory tests (subject to the judgment of the clinical study physician);
  19. Patients with active tuberculosis suggested by clinical symptoms, signs, laboratory tests or chest radiography at screening;
  20. Patients whose white blood cell count, , lymphocyte count or in blood routine examination exceed the normal reference range and have clinical significance judged by the investigator;
  21. May increase study-related risks, may interfere with interpretation of study results, or, in the judgment of the investigator, make the investigator and/or sponsor unsuitable for enrollment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    QLM3003

    QLM3003 Single dose

    Drug: QLM3003

  • Placebo comparator
    QLM3003 Placebo

    QLM3003 vehicle Single dose

    Drug: QLM3003 Placebo

Interventions

  • DrugQLM3003

    1%(10g∶0.1g)or 1.5%(10g∶0.15g)or 2%(10g∶0.2g)

  • DrugQLM3003 Placebo

    1%(10g∶0.1g)or 1.5%(10g∶0.15g)or 2%(10g∶0.2g)(matching corresponding study medication)

06

What researchers measure

Primary outcomes

  1. Incidence (severity and causality) of any local and systemic adverse events

    adverse events

    Time frame: 8 days

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of QLM3003

    Cmax

    Time frame: 8 days

  2. Area Under the Plasma Concentration-Time Curve From 0 to t of QLM3003

    AUC0-t

    Time frame: 8 days

  3. Area Under the Plasma Concentration-Time Curve From 0 to infinity of QLM3003

    AUC0-∞

    Time frame: 8 days

07

Study locations

1 site
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Aug 2023, 1 month.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 1 month is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2023
First posted
Jul 6, 2023
StartActual
Jun 25, 2023
Primary completionActual
Aug 5, 2023
CompletionActual
Aug 30, 2023
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05932888
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Jun 25, 2023
Primary completion
Aug 5, 2023
Completion
Aug 30, 2023
Last update
Sep 21, 2023

Study contacts

guoping Yang, doctor
study director · The Third Xiangya Hospital of Central South University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion